- NMX East, a lithium property tied to Nemaska Lithium Inc.’s (TSX.V-NMX) Whabouchi property in Quebec.
- NMX East property has all season road access via the Route Nord.
- located within a few kilometres of Nemaska’s proposed mining pit.
- Nemaska Lithium is developing the world’s newest lithium mine in Quebec and has signed agreements with its key stakeholders, gained the required permits and was recently awarded both Federal Environmental Approval and the Province of Quebec Mine Approval.
- Whabouchi Spodumene Mine with 23Mt Proven and Probable @ 1.53% Li
Posts Tagged ‘$TSXV’
INTERVIEW: Durango Discusses NMX East Work Program. Property Tied to Nemaska Lithium Whabouchi Property in Quebec $DGO.ca $NMX.ca
Pacific North West Capital Acquires 100% Interest in Eagle Pegmatite, SE Manitoba; Part of the Lithium Two Project $PFN.ca
American Creek Reports That Drilling Has Commenced at Treaty Creek $AMK.ca
GrowPros Announces the Closing of a Non-Brokered Private Placement $GCI.ca
- Announced the closing of a non-brokered private placement of 2,160,000 units at a price of $0.05 per unit for aggregate gross proceeds of $108,000
- Unit consists of one common share and one transferable warrant, with a whole warrant entitling the holder to purchase one common share at a price of $0.07 for a period of twenty-four months expiring August 15, 2018
OTTAWA, ONTARIO–(Aug. 15, 2016) – GrowPros Cannabis Ventures Inc. (“GrowPros” or “the Company”) (CSE:GCI) announces the closing of a non-brokered private placement of 2,160,000 units at a price of $0.05 per unit for aggregate gross proceeds of $108,000. Each unit consists of one common share and one transferable warrant, with a whole warrant entitling the holder to purchase one common share at a price of $0.07 for a period of twenty-four months expiring August 15, 2018.
In connection with the private placement, the Company will pay a cash finder’s fee of $4,250 and will issue 85,000 non-transferable finder’s warrants. Each finder’s warrant entitles the holder to purchase one common share of the Company at a price of $0.07 per share for a period of twenty-four months expiring August 15, 2018.
Two insiders participated in the private placement by purchasing 1,000,000 units for a total of $50,000.
The securities issued pursuant to the private placement are subject to a four-month hold period from the closing date and subject to all necessary regulatory approvals, including the approval of the Exchange.
The proceeds of the private placement will be used to fund general working capital.
The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Ryan Brown
Chief Executive Officer
(613) 421-8402
Durango Phase One Exploration Completed at Nemaska Properties $DGO.ca
CLIENT FEATURE: #1 Vaporizer Distributor in Europe, $5.8M USD of Revenue Run Rate $N.ca


- #1 vaporizer distributor in Europe
- $5.8M USD of revenue run rate
- Proprietary products launched
- Perfect market timing for expansion


- International ecommerce distribution
- 30+ International based portals
- 10 Languages
- Proprietary vaporizer products
- Targeting organic growth at 100% per year
- Sourcing accretive M & A transactions

Regulation
- Decriminalization and destigmatization of marijuana for medical and recreational use in US, Canada and Europe
- Vaporizers have lower regulatory burden than growers
Health Advantages


Technical Advances
- Improved mobility from reduced size of vaporizers
- Ability to handle liquids, resins and plant matters
- Conduction, convection, induction technologies
- Mobile connectivity
- Increasingly becoming part of the internet of things













FEATURE: GrowPros (GCI:CSE) Natural Pharmaceuticals From Cannabis and Other Medicinal Plants $GCI.ca

Natural Pharmaceuticals Derived From Cannabis and Other Medicinal Plants
Comprised Of Two Divisions
Pharmaceutical Division – PhytoPain Pharma
- A new subsidiary created June 2, 2016. 80% Ownership
- Mission is the development and commercialization of botanical based pharmaceuticals
- A clinical stage drug development company engaged in the development of medication to alleviate symptoms related to: Pain,
Insomni, anxiety disorder, in patients suffering from Cancer and othe, chronic and terminal diseases
Dr Guy Chamberland, Chief Scientific Officer and Regulatory Affairs
- Professor of herbal medicine and clinical research at the École d’Enseignement Supérieur de Naturopathie du Québec.
- 22 years’ experience in the pharmaceutical and natural product industries includes successful development of intellectual property for several botanical drug products
WHY DOCTORS NEED PHARMA MARIJUANA SOLUTIONS
- A Physician’s decision to prescribe a new drug or even a natural health product has to be based on Evidence-Based Medicine > A legal, ethical requirement
- Currently, no body of evidence exists to not support the prescription or recommendation of medical marijuana in any medical condition, including terminal cancer
- The GrowPros pharmaceutical product development plan would provide the data necessary for physicians to prescribe or recommend our products
PRODUCT PIPELINE
Insomnia Management For Patients With Chronic Pain
- Licensed a hypnotic drug from Mondias Naturals Inc
- Management of Insomnia in patients with chronic pain
- Currently in late stage Phase III clinical testing
PhytoPain To Produce A Combination Product
- Proprietary combination expected to reach Phase I clinical testing in 2017
- Will be ready for market in 2017 due to combination with Mondias Naturals product
Pain Management – Inhalation Cannabis Drug Product
- A prescription drug for management of uncontrolled pain in cancer patients
- Health Canada will provide guidance during Phase I clinical trial
- Commencing December 2016. Anticipating 3-5 year product development
A recent discussion with the Quebec College of Physicians confirms that pharmaceutical development of a medical marijuana for inhalation would be well received by the medical community.
OPERATIONS OVERVIEW – MMPR
MMPR Division – Collaboration Agreement
- March 18, 2016 – Signed agreement with Delta 9 Bio-Tech, a “Licensed Producerâ€
- Delta 9 will submit to Health Canada an Amendment to collaborate on GrowPros previous application for facility in Southern Quebec; Amendment submission anticipated by June 30, 2106, Health Canada response anticipated August 30, 2016
- Key Benefits of Delta 9 Collaboration: Significant process clarity, High probability of success eliminates spec construction risk, Single customer through option to acquire all dried marijuana product for 2 years
- Key strategic benefit to GrowPros; Controlled production, quality and supply for Pharma Division, Value of license, Wholesale seller vs. retail seller
12 Month Stock Chart

INTERVIEW: Explor Resources Discusses Flagship Property Hosting 609k oz Indicated 470K oz Inferred Gold $EXS.ca $TCK.ca
- NI 43-101 Resource: 609,000 oz Indicated
470,000 oz Inferred Gold - 13 km from downtown Timmins
- Property is 2.5 km, NE of West Timmins Mine
- Model: Hollinger McIntyre Gold System: 30,000,000 oz. Au
- Discovery Hole 10-30 : 9.22g/tonne over 11.0 meters
- Optioned to Teck Resources
- Teck to spend $12,000,000 to earn 70% interest
INTERVIEW: HPQ Silicon Discusses PURVAP IP Acquisition. $8 Million Deal $HPQ.ca
HPQ Silicon is also the largest holder of High Purity Quartz properties in Quebec, with over 3,500 Ha under claims. Despite the abundance of quartz, very few deposits are suitable for high purity applications. High Purity Quartz supplies are tightening, prices are rising, and exponential growth is forecast. Quartz from the Roncevaux property successfully passed rigorous testing protocols of a major silicon metal producer confirming that our material is highly suited for their silicon metal production.
KWG Files Notice of Sale From Control of Debut Diamonds $KWG.ca
- Notice of Sale from Control with respect to all of its 144,630,000 common shares of affiliate Debut Diamonds Inc.
- Notice provides that the shares will be sold either in whole or in part and either privately or through the facilities of the Canadian Securities Exchange stock market.
TORONTO, ONTARIO–(Aug. 5, 2016) – KWG Resources Inc. (CSE:KWG)(FRANKFURT:KW6) (“KWG”) has filed a Notice of Sale from Control with respect to all of its 144,630,000 common shares of affiliate Debut Diamonds Inc. (CSE: DDI) (“Debut”). The notice provides that the shares will be sold either in whole or in part and either privately or through the facilities of the Canadian Securities Exchange stock market.
About Debut:
Debut has both joint-ventured and wholly-owned diamond exploration properties that include the previously discovered MacFadyen and Good Friday kimberlite pipes within claims contiguous to the DeBeers claim block containing the Victor Diamond Mine. Debut also has an interest in the diamond bearing Kyle kimberlites about 100 kilometers to the west. See more at: http://www.debutdiamonds.com/docs/2015/01/debut-diamonds-inc-completes-private-placement-3/#sthash.CuirzLLh.dpuf
About KWG:
KWG has a 30% interest in the Big Daddy chromite deposit and the right to earn 80% of the Black Horse chromite where resources are being defined. KWG also owns 100% of CCC which has staked claims and conducted a surveying and soil testing program, originally for the engineering and construction of a railroad to the Ring of Fire from Aroland, Ontario. KWG subsequently acquired intellectual property interests, including a method for the direct reduction of chromite to metalized iron and chrome using natural gas. KWG subsidiary Muketi Metallurgical LP is prosecuting two chromite-refining patent applications in Canada, China, India, Indonesia, Japan, Kazakhstan, South Africa, South Korea, Turkey, and USA. The filings have been receipted in each of those jurisdictions.
Shares issued and outstanding: 961,320,281
Bruce Hodgman
Vice-President
416-642-3575
[email protected]











